Structural and compositional modifications of diabetic low-density lipoproteins influence their receptor-mediated uptake by hepatocytes

European Journal of Clinical Investigation

Volumn 27, Issue 6, 1997, Pages 460-468

  Kramer Guth A ^a   Quaschning, T ^a   Galle, J ^a   Baumstark, M W ^a   Koniger M ^a   Nauck, M ^a   Schollmeyer, P ^a   Marz W ^a   Wanner, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Atherosclerosis; Glycation; Low density lipoprotein receptor; Low density lipoprotein subfractions; Modified low density lipoprotein

Indexed keywords

LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; LIPID ANALYSIS; LIPID COMPOSITION; LIVER CELL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN GLYCOSYLATION;

EID: 0030818862     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1997.1460695.x     Document Type: Article

References (41)

1. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524.
2. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein B-kinetics in non-insulin-dependent diabetes mellitus. Diabetes 1982;31:217-25.
3. Barrett-Connor E, Grundy SM, Holdbook MJ. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol 1982;115:657-63.
4. Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 1992;41(suppl. 2):12-17.
5. Manzato E, Zambon S, Zambon A, Cortella A, Sartore G, Crepaldi G. Levels and physico-chemical properties of lipoprotein subclasses in moderate hypertriglyceridemia. Clin Chim Acta 1993;218:57-65.
6. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992;12:1496-502.
7. Chait A, Braszg RL, Tribble DL, Krauss RM. Susceptibility of small dense low density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993;94:350-6.
8. Kleinman Y, Eisenberg S, Oschry Y, Gavish D, Stein O, Stein Y. Defective metabolism of hypertriglyceridemic low density lipoprotein in cultured human skin fibroblasts. J Clin Invest 1985;75:1796-803.
9. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 1993; 102:63-7.
10. Sasaki J, Cottam GL. Glycosylation of LDL decreases its ability to interact with high affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma in vivo. Biochim Biophys Acta 1982;713:199-207.
11. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991;32:1741-53.
12. Lipid Research Clinics Program. Manual of laboratory operation. DHEW No. (NIH) 75-628. Bethesda: National Heart and Lung Institute 1971;1-74.
13. Wanner C, Hörl WH, Luley C, Wieland H. Effect of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 1991;39:754-60.
14. Luley C, Baumstark MW, Wieland H. Rapid apolipoprotein E phenotyping by immunofixation in agarose. J Lipid Res 1991;32:880-3.
15. 3500 → Gln) allele specific PCR. Large scale screening of pooled blood samples. J Lipid Res 1992;33:1563-7.
16. Hansen PS, Rüdiger N, Tybjaerg-Hansen A, Faergeman O, Gregersen N. Detection of the apoB-3500 mutation (glutamine for arginine) by gene amplification and cleavage with Mspl. J Lipid Res 1991;32:1229-33.
17. Shea EA, Cohen MP. Immunologic detection and measurement of glycated apolipoprotein B with site specific antibodies. J Immunol Methods 1993;162:85-95.
18. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human plasma. J Clin Invest 1955;34:1345-53.
19. McFarlane AS. Efficient trace labelling of proteins with iodine. Nature 1958;182:53-6.
20. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta 1972;260:212-21.
21. Makino K, Furbee JW Jr, Scanu AM, Fless GM. Effect of glycation on the properties of lipoprotein (a). Arterioscler Thromb Vasc Biol 1995;15:385-91.
22. Esterbauer H, Striegel G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radical Res Commun 1989;6:67-75.
23. Ohkawa H, Ohishi N, Yagi M. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
24. Lindgren FT. Preparative ultracentrifuge laboratory procedures and suggestions for lipoprotein analysis. In: Perkins EG, ed. Analysis of lipids and lipoproteins. Champaign IL: American Oil Chemists' Society, 1984;204-24.
25. Baumstark MW, Kreutz W, Berg A, Frey I, Keul J. Structure of human low-density lipoprotein subfractions determined by X-ray small-angle scattering. Biochim Biophys Acta 1990;1037:48-57.
26. Goldstein JL, Basu JK, Brown US. Receptor-mediated endocytosis of low density lipoprotein in cultured cells. In: Fischer S, Fleischer B, eds, Methods in enzymology. Vol. 98. New York: Academic Press, 1983;241-60.
27. Krämer-Guth A, Nauck M, Pavenstädt H, Königer M, Wieland H, Schollmeyer P, Wanner C. Preferential uptake of intermediate-density lipoproteins from nephrotic patients by human mesangial and liver cells. J Am Soc Nephrol 1994;5:1081-90.
28. März W, Baumstark MW, Scharnagel H et al. Accumulation of small dense low density lipoproteins in a homozygous patient with familial defective apolipoproteinB-100. Results from heterozygous interaction of low density lipoprotein subfractions with the LDL-receptor. J Clin Invest 1993;92:2922-33.
29. Lyons T. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993;71:26B-31B.
30. Galeano NF, Milne R, Marcel YL et al. Apoprotein-B structure and receptor recognition of triglyceride rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride rich LDL of normal size. J Biol Chem 1993;269:511-19.
31. DeGraaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arteriosclerosis 1991;11:298-306.
32. DeJager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993;34:295-302.
33. Aviram M, Lund-Katz S, Phillips MC, Chait A. The influence of the triglyceride content of low density lipoprotein on the interaction of apolipoproteinB-100 with cells. J Biol Chem 1988;263:16842-8.
34. Young SG. Recent progress in understanding apolipoproteinB. Circulation 1990;82:1574-94.
35. Hiramatsu K, Bierman EL, Chait A. Metabolism of low density lipoprotein from patients with diabetic hypertriglyceridemia by cultured human skin fibroblasts. Diabetes 1985;34:8-14.
36. Lopes-Virella MF, Sherer GK, Lees AM et al. Surface binding, internalization and degradation by cultured human fibroblasts of LDL isolated from type I diabetic patients: changes with metabolic control. Diabetologia 1982;22:430-6.
37. Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, Cerami A, Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994;91:9441-5.
38. Triau JE, Arbetter J, Schäfer EJ. Impaired hepatocyte binding, uptake and degradation of glycosylated low density lipoproteins. Biochim Biophys Acta 1986;877:359-65.
39. Schleicher E, Wieland OH. Specific quantitation by HPLC of protein (lysine) bound glucose in human serum albumin and other glycated proteins. J Clin Chem Clin Biochem 1981;19:81-7.
40. Steinbrecher UP, Witztum JL. Glucosylation of LDL to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984;33:130-4.
41. Manzato E, Zambon A, Lapolla A, Zambon S, Braghetto L, Crepaldi G, Fedele D. Lipoprotein abnormalities in well-treated type II diabetic patients. Diabetes Care 1993;16:469-75.